Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."

Most Recent Videos

Tsipras: Won’t Be Clash or Kowtowing With Creditors
46:32 - Jan. 29 -- Greek bank stocks rebounded as the government moved to contain the fallout from pledges made by its ministers, seeking to downplay the prospect of an imminent clash with creditors. Bloomberg’s Michael McKee reports on “Bloomberg Surveillance.”
  • Spongebob: Who Lives in a Pineapple on Your TV?
  • Truck Drivers Protest Wages and Block Traffic
  • Arab Spring and Failed States: Charlie Rose (01/29)